Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

Airway inflammation

Article Abstract:

Understanding the role and mechanism of inflammation in long-term airway diseases such as asthma and chronic bronchitis may lead to more effective treatments for these diseases. Researchers presented current research on the role of cytokines and viral infection in the inflammation process and proposed several models to explain how this process may operate in patients with long-term airway diseases. The tissue cells that line the airways produce inflammatory proteins called cytokines as well as acids and enzymes that may either stimulate or increase the intensity of the immune response responsible for the inflammation process. Viral infections may also enhance the inflammation process. A cycle of recruiting specialized cells to the airways to initiate and maintain the immune response may explain the mechanism of airway inflammation.

Author: Kaliner, Michael A., Rennard, Stephen I., Shelhamer, James H., Levine, Stewart J., Wu, Tong, Jacoby, David B.
Publisher: American College of Physicians
Publication Name: Annals of Internal Medicine
Subject: Health
ISSN: 0003-4819
Year: 1995
Physiological aspects, Diseases, Inflammation, Airway obstruction (Medicine), Airway obstruction, Airway (Medicine), Airway

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Lipid formulations for amphotericin B: does the Emperor need new clothes?

Article Abstract:

Three new formulations of the drug amphotericin B used to treat fungus infections may be equally effective and less toxic but may be difficult to acquire due to increased cost. Various techniques incorporating the drug inside fat molecules called liposomes seem to reduce the toxic effects to the kidney. Preliminary studies have shown that amphotericin B and the other formulations including amphotericin B lipid complex (ABLC) and amphotericin B in true liposomes (AMB1) are similarly effective with response rates ranging from 60%-65%. However, the cost of these new formulations can approach $1,000 a day. Currently, the US has licensed ABLC for use in treating aspergillosis but only as a second-choice treatment.

Author: Graybill, John R.
Publisher: American College of Physicians
Publication Name: Annals of Internal Medicine
Subject: Health
ISSN: 0003-4819
Year: 1996
Health aspects, Editorial, Usage, Liposomes, Amphotericin B

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Similar abstracts:
  • Abstracts: Intestinal infarction after intravenous cocaine administration. Potentiation of cocaine-induced coronary vasoconstriction by beta-adrenergic blockade
  • Abstracts: Radiation treatment of cerebral arteriovenous malformations. Stereotactic heavy-charged-particle Bragg-peak radiation for intracranial arteriovenous malformations
  • Abstracts: Efficacy and toxicity of sodium stibogluconate for mucosal leishmaniasis. War syndromes and their evaluation: from the U.S. Civil War to the Persian Gulf War
  • Abstracts: Changes in psychosocial adjustment after renal transplantation. Psychological guidelines in the management of paediatric organ transplantation
  • Abstracts: Drugs for hypertension
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.